Education and Training
PRP as Adjuvant Treatment to CTR for Severe CTS Tunnel Syndrome
This study assesses the potential benefit of adjuvant platelet-rich plasma (PRP) with carpal tunnel release (CTR) for patients with severe carpal tunnel syndrome (CTS). CTR is a rather common procedure performed and seems to be quite effective for those with moderate CTS, but a number of patients with severe CTS do not have quite the same response post-CTR. The investigators will recruit patients who fall into the severe CTS category and compare CTR with and without adjuvant PRP to see if PRP can improve outcomes of this common surgery.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Carpal Tunnel Release with Platelet-Rich Plasma
- procedure: Carpal Tunnel Release without Platelet-Rich Plasma
Eligibility
Inclusion Criteria:
1. Adult age 18 years and up.
2. Diagnosed with severe CTS based on EMG/NCS, meaning those with evidence of axonal loss
(absent or low amplitude median sensory nerve action potential and/or absent or low
amplitude median motor nerve action potential and/or evidence of abnormal spontaneous
activity, reduced recruitment, or motor unit action potential changes on needle EMG of
median innervated muscles).
Exclusion Criteria:
1. Younger than age 18 years (minor status).
2. Diagnosed with concomitant peripheral neuropathy.
3. Previous CTR on the affected side.
4. Have contraindications to PRP (platelet dysfunction syndrome, critical
thrombocytopenia, hemodynamic instability, septicemia, local infection at site of
procedure, consistent use of NSAIDs within 48 hours of procedure, steroid injection at
treatment site within 1 month, systemic use of steroids within 2 weeks, tobacco use,
recent fever or illness, or cancer).
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting